Your monthly Breyanzi cost savings if eligible
With our assistance, you could access the Breyanzi patient assistance program and obtain your medication for free. We only charge a flat monthly fee of $49 per medication for our services.
Am I eligible for Breyanzi patient assistance?
We review each Breyanzi enrollment application individually to determine if you are eligible. Each assistance program has its own eligibility criteria and the factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Breyanzi patient assistance program?
Our process makes it as easy as possible to apply for the Breyanzi patient assistance program. Begin by completing the enrollment application form on our website. Tell us about any medications that you are taking, including Breyanzi, your healthcare provider, your insurance plan, and your household income. This information is required by the pharmaceutical manufacturers who will supply the medication, so it is important to make sure this information is accurate and up to date.
We will review the information that you have provided to determine whether you are eligible for patient assistance. If we can pre-qualify you for assistance, NiceRx will handle the full enrollment process on your behalf. If you are approved by the pharmaceutical company, you will typically start receiving your medication in 6 – 8 weeks.
Is NiceRx a Breyanzi coupons provider?
NiceRx is not a Breyanzi coupon, Breyanzi discount card, or Breyanzi copay card provider. We do not offer Breyanzi manufacturer coupons, Breyanzi discounts, rebates, Breyanzi savings cards, trial offers, or free Breyanzi samples. We are a service provider that helps eligible individuals access their medication directly from the U.S. pharmaceutical company.
Can NiceRx help me if I have insurance?
NiceRx may be able to help you if:
- You have a high copay or coinsurance responsibility for Breyanzi
- Your insurance company will not pay for your Breyanzi prescription
- Your healthcare plan does not cover your medication
- You do not have insurance
Please apply online to find out if we can help you.
How much does Breyanzi cost without insurance?
Without insurance, Breyanzi costs will vary depending on where you buy the medication as prices will vary by retailer. As a guide, Breyanzi intravenous suspension will cost around $428,000 for a supply of 1 suspension.
How much does Breyanzi cost with insurance?
The copay for Breyanzi will depend on the terms of your healthcare plan. Your healthcare provider or pharmacist will be able to calculate your copay with your current insurance. Contact them to find out more.
What is Breyanzi?
Approval of Breyanzi was granted by the FDA (U.S. Food and Drug Administration) to Juno Therapeutics Inc a Bristol-Myers Squibb Company (BMS).
Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (LBCL), and follicular lymphoma grade 3B.
What doses of Breyanzi are available?
Breyanzi is available as a cell suspension for infusion, in the following doses: A single dose of Breyanzi contains 50 to 110 × 106 CAR positive viable T cells (consisting of 1:1 CAR-positive viable T cells of the CD8 and CD4 components), with each component, supplied separately in one to four single-dose 5 mL vials. Each mL contains 1.5 × 106 to 70 × 106 CAR-positive viable T cells.
Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurs in patients receiving treatment. Do not give Breyanzi to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids. Neurologic toxicities, including fatal or life-threatening reactions, occur in patients receiving Breyanzi, including with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with Breyanzi. Provide supportive care and/or corticosteroids as needed. Breyanzi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Breyanzi REMS.
Patients should be monitored daily at a certified healthcare facility during the first week of treatment, for signs and symptoms of CRS and neurologic toxicities. Please see full prescribing information, including Boxed warnings and a medication guide.
Always speak with your healthcare provider about any changes to your dose so they can monitor and evaluate your condition.
Breyanzi active ingredients
The active ingredient of Breyanzi is lisocabtagene maraleucel. It is classed as a chimeric antigen receptor, CAR T cell therapy.
The CAR is comprised of an FMC63 monoclonal antibody-derived single-chain variable fragment (scFv), IgG4 hinge region, CD28 transmembrane domain, 4-1BB (CD137) costimulatory domain, and CD3 zeta activation domain.
Breyanzi side effects
The most common side effects of Breyanzi in clinical trials include:
- Cytokine release syndrome
- Musculoskeletal pain
- Nausea, headache
- Decreased appetite, diarrhea, constipation, abdominal pain, vomiting
- Hypotension, tachycardia, dizziness
In rare instances, Breyanzi can cause more serious adverse events. These can include:
- Hypersensitivity Reactions
- Serious Infections
- Secondary Malignancies
- Effects on ability to drive and use machines – advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery for at least 8 weeks after treatment
Your doctor will assess the benefits of using Breyanzi against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Breyanzi to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Breyanzi drug interactions
Breyanzi can interact with other medications. These include:
- Live vaccines – BCG, measles, mumps, rubella, smallpox
- Corticosteroids – prednisolone, hydrocortisone, mometasone, dexamethasone, cortisone
This list is not exhaustive and other drugs may interact with Breyanzi.
You should not use Breyanzi if you:
- Are allergic to the active ingredient lisocabtagene maraleucel
- Are allergic to any of the other ingredients in Breyanzi
Talk to your doctor before using Breyanzi if you:
- Are taking any of the medications that could interact with Breyanzi
- Are pregnant or are planning to become pregnant
- Are breastfeeding or are planning to breastfeed
Breyanzi is the trademark brand name for lisocabtagene maraleucel manufactured by the Bristol-Myers Squibb Company (BMS). A generic version of lisocabtagene maraleucel is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Breyanzi savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.